bi-d

(±)-BI-D is an effective ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site (IC50: 2.4–2.9 μM).

BI-69A11 ((E)-3-(1H-Benzo[d]imidazol-2-yl)-1-(6-chloro-2-hydroxy-4-phenylquinolin-3-yl)prop-2-en-1-one) is a dual AKT and NFkB pathway inhibitor. It enhances the susceptibility of colon cancer cells to mda-7/IL-24-induced growth inhibition by targeting Akt.

BI 6015 is an antagonist of HNF4α. HNF4α is a nuclear receptor that regulates gene expression in the intestine cells, liver cells, and pancreas-β cells.

BI-D1870 is a highly specific, blood-brain-permeable, and ATP-competitive inhibitor of the N-terminal AGC kinase domain of RSK, with IC50 values ​​of 31 nM, 24 nM, 18 nM, and 15 nM for RSK1, RSK2, RSK3, and RSK4.

OUN58101, also known as MDK-8101, also known as BI-D, is a RSV L-protein inhibitor. OUN58101 was first reported in patnet WO 2005042530. This product has no formal name at the moment. For the convenience of communication, a temporal code name was therefore proposed according to MedKoo Chemical Nomenclature (see web page: https://www.medkoo.com/page/naming).

Miptenalimab (BI-754111) is an anti-human LAG-3 antibody with a dissociation constant (K D) of 88.6 nM for h LAG-3, effectively blocking the interaction between LAG-3 and its ligand MHC-II [1].